RxSight, Inc. (RXST)Healthcare | Medical Devices | Aliso Viejo, United States | NasdaqGM
5.06 USD
+0.11
(2.222%)
⇧
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 4:43 a.m. EDT
The investment case for RxSight is currently broken by a catastrophic collapse in market valuation and deteriorating operational metrics. While the company secured a notable partnership with Alcon, the stock has erased nearly 84% of its value year-to-date, trading at a fraction of its previous highs despite the deal. Fundamentally, the business is bleeding cash with negative operating margins and shrinking revenue, while the balance sheet remains fragile with negative free cash flow. The technical picture confirms this distress, with the price trading well below both its 50-day and 200-day moving averages, signaling persistent selling pressure. Although the recent price action shows a slight bounce off the lows, the underlying fundamentals—negative earnings, declining sales, and a lack of dividend support—make this a high-risk situation where the market is correctly pricing in further uncertainty. Investors should avoid adding to the pile until there is clear evidence of a turnaround in profitability and revenue growth. |
| Model | MAE |
|---|---|
| MSTL_73_95 ✓ | 0.142239 |
| MSTL_73 | 0.193387 |
| AutoETS | 0.236665 |
| AutoARIMA | 0.236670 |
| AutoTheta | 0.236793 |
| MSTL | 0.243745 |
| MSTL_95 | 0.244451 |
Forecast horizon: 60 days | Selected: MSTL_73_95
| Forecast Reliability | |
|---|---|
| Score | 35% |
| H-stat | 3.37 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.109 |
| Excess Kurtosis | -1.10 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 4.05 |
| Revenue per Share | 3.105 |
| Market Cap | 209,466,832 |
| Forward P/E | -9.04 |
| Beta | 1.15 |
| Profit Margins | -36.59% |
| Website | https://rxsight.com |
As of July 11, 2026, 4:43 a.m. EDT: Speculators are heavily positioned for downside protection, with significant open interest in out-of-the-money puts at the $2.50 strike for September expiration, indicating a fear of a deeper decline. Conversely, call activity is almost entirely concentrated at the money ($5.00), suggesting traders are hedging existing positions rather than betting on a rally. The lack of speculative volume in calls above the current price contrasts sharply with the defensive posture of put buyers.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.3604651 |
| Address1 | 100 Columbia |
| All Time High | 66.54 |
| All Time Low | 4.48 |
| Ask | 6.31 |
| Ask Size | 2 |
| Audit Risk | 3 |
| Average Analyst Rating | 3.1 - Hold |
| Average Daily Volume10 Day | 2,177,920 |
| Average Daily Volume3 Month | 1,042,924 |
| Average Volume | 1,042,924 |
| Average Volume10Days | 2,177,920 |
| Beta | 1.146 |
| Bid | 3.75 |
| Bid Size | 2 |
| Board Risk | 5 |
| Book Value | 6.459 |
| City | Aliso Viejo |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 5.06 |
| Current Ratio | 10.2 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 5.25 |
| Day Low | 4.886 |
| Debt To Equity | 4.05 |
| Display Name | RxSight |
| Earnings Call Timestamp End | 1,778,099,400 |
| Earnings Call Timestamp Start | 1,778,099,400 |
| Earnings Timestamp | 1,785,960,000 |
| Earnings Timestamp End | 1,785,960,000 |
| Earnings Timestamp Start | 1,785,960,000 |
| Ebitda | -52,022,000 |
| Ebitda Margins | -0.40809 |
| Enterprise To Ebitda | -0.046 |
| Enterprise To Revenue | 0.019 |
| Enterprise Value | 2,412,841 |
| Eps Current Year | -0.7 |
| Eps Forward | -0.56 |
| Eps Trailing Twelve Months | -1.13 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 5.5321 |
| Fifty Day Average Change | -0.47210026 |
| Fifty Day Average Change Percent | -0.08533834 |
| Fifty Two Week Change Percent | -36.046513 |
| Fifty Two Week High | 13.22 |
| Fifty Two Week High Change | -8.16 |
| Fifty Two Week High Change Percent | -0.61724657 |
| Fifty Two Week Low | 4.48 |
| Fifty Two Week Low Change | 0.5799999 |
| Fifty Two Week Low Change Percent | 0.12946427 |
| Fifty Two Week Range | 4.48 - 13.22 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,627,651,800,000 |
| Float Shares | 39,089,990 |
| Forward Eps | -0.56 |
| Forward P E | -9.035714 |
| Free Cashflow | -969,250 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 461 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.77015996 |
| Gross Profits | 98,178,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.06448 |
| Held Percent Institutions | 0.9314 |
| Implied Shares Outstanding | 41,396,609 |
| Industry | Medical Devices |
| Industry Disp | Medical Devices |
| Industry Key | medical-devices |
| Ipo Expected Date | 2,021-07-30 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was incorporated in 1997 and is headquartered in Aliso Viejo, California. |
| Long Name | RxSight, Inc. |
| Market | us_market |
| Market Cap | 209,466,832 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_62603649 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -46,638,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 204,913,214 |
| Number Of Analyst Opinions | 7 |
| Open | 4.93 |
| Operating Cashflow | -17,570,000 |
| Operating Margins | -0.57712 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 949 521 7830 |
| Previous Close | 4.95 |
| Price Eps Current Year | -7.2285714 |
| Price Hint | 2 |
| Price To Book | 0.783403 |
| Price To Sales Trailing12 Months | 1.6431736 |
| Profit Margins | -0.36585 |
| Quick Ratio | 8.779 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | hold |
| Recommendation Mean | 3.11111 |
| Region | US |
| Regular Market Change | 0.11 |
| Regular Market Change Percent | 2.22223 |
| Regular Market Day High | 5.25 |
| Regular Market Day Low | 4.886 |
| Regular Market Day Range | 4.886 - 5.25 |
| Regular Market Open | 4.93 |
| Regular Market Previous Close | 4.95 |
| Regular Market Price | 5.06 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 782,000 |
| Return On Assets | -0.11212 |
| Return On Equity | -0.17063999 |
| Revenue Growth | -0.185 |
| Revenue Per Share | 3.105 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 41,396,609 |
| Shares Percent Shares Out | 0.13319999 |
| Shares Short | 5,513,925 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 4,171,123 |
| Short Name | RxSight, Inc. |
| Short Percent Of Float | 0.14060001 |
| Short Ratio | 4.1 |
| Source Interval | 15 |
| State | CA |
| Symbol | RXST |
| Target High Price | 11.0 |
| Target Low Price | 6.5 |
| Target Mean Price | 8.42857 |
| Target Median Price | 8.0 |
| Total Cash | 217,880,000 |
| Total Cash Per Share | 5.263 |
| Total Debt | 10,826,000 |
| Total Revenue | 127,477,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.13 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 8.077225 |
| Two Hundred Day Average Change | -3.0172248 |
| Two Hundred Day Average Change Percent | -0.37354723 |
| Type Disp | Equity |
| Volume | 782,000 |
| Website | https://rxsight.com |
| Zip | 92,656 |